Form 4/A for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-04-28 00:00:00 ET · period of report 2023-04-03 · accession 0001209191-23-026049 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2023-04-28 | 2023-04-03 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +1,996 | 57.6K | +4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-04-03 | A | A | 1,996 | $0.00 | 57,569 | D | — | — | (F1) The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. (F2) Includes a total of 35,008 shares received pursuant to a pro-rata distribution from Lux Ventures, of which the Reporting Person was a limited partner. The acquisition of such shares was exempt pursuant to Rule 16a-9 and was inadvertently excluded from the total amount of shares held on the original Form 4 filing. |